Today, we will take a detailed look into a company that has an imminent catalyst, a number of important Phase II and Phase III data releases throughout 2013, and a product pipeline with potential to tap into a $17B market.…
Approaching Biopharma Catalyst Events
Today, I list 4 biopharmas I feel offer strong upside potential in the short and midterm. With these catalysts quickly approaching, we can expect some nice shorter term appreciation under normal market conditions. I feel the 4 stocks I list…
Cleveland BioLabs Offers Medical Countermeasures Against Potential Terrorist Attacks.
Sadly, terrorism is a real threat to the United States homeland as we just saw last week. However, we can take a little solace in the fact that the recent terrorist attack involved crude homemade non-radiological bombs. The fact remains…
Weekend update with some charts, Market forecast and opinion. (VIDEO)
Weekend update with some charts, $AVEO $ATRS $ARNA $ACRX briefly covered. Market forecast and opinion. YouTube Video
AVEO Poised To Move Higher Before FDA Adcomm Catalyst, Obamacare And Platform Potential
The advent of The Affordable Care Act (Obamacare) is on the horizon as the healthcare sector of the market continues its strong rally. With new Food and Drug Administration (FDA) regulatory easing, congressional bills, and The Obama Administration directive in…
I bought $BDSI.. Chart with basic DD
BDSI is such a compelling prospect for a short term investment for a couple of different reasons. The most important reason being a major catalyst coming mid 2013. BDSI is anticipating a mid-year filing of an NDA for BUNAVAIL(tm) for the…
Updated: (cleaned up) Market Historical Chart For Review: Economic Commentary and Market Forecast Opinion.
Above, we can see an historical chart of The Dow going back to 2003. Take note of the current market trend and compare to past trends. I feel the market needs a correction and is over extended on the QE…
AVEO Pharma’s Tivozanib Likely To Be Approved
With the current record market run, small cap biopharmas have kept pace and continue to trend higher, being one of the best sectors for both trading and investing over the past year. With 39 new drugs approved, 2012 showed the…
$AVEO Due Diligence: Catalyst: Adcomm May 2nd
2 days ago, I issued a bullish chart alert for $Aveo. Some basic DD on Aveo: First off, one of the best articles covering Aveo’s tivozanib, which is designed as a front line treatment for metastatic renal cell carcinoma (RCC)…
Trading call: $OPXA- Price target opinion – $2.50
Trading call: $OPXA- Price target opinion – $2.50 More coverage to come
